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toxic effects on fly lifespan and climbing ability, further 
suggesting that Aβ43 peptides could act as a nucleating fac-
tor in AD brains. Altogether, our study demonstrates high 
pathogenicity of Aβ43 species in vivo and supports the idea 
that Aβ43 contributes to the pathological events leading to 
neurodegeneration in AD.
Keywords Alzheimer’s disease · Amyloid-β · Drosophila 
models · Neurodegeneration · Neurotoxicity
Introduction
Alzheimer’s disease (AD) is a devastating neurodegen-
erative disorder characterized by the presence of two 
neuropathological hallmarks, namely the intraneuronal 
deposition of hyperphosphorylated Tau proteins into neu-
rofibrillary tangles and accumulation of Aβ peptides both 
intracellularly and into extracellular amyloid plaques. Aβ 
peptides are produced following the sequential proteolytic 
cleavage of their precursor protein, APP, by secretases. The 
cleavage releasing the C-terminal part of Aβ can occur at 
different residues and hence produce peptides of differ-
ent lengths, ranging from 37 to 49 amino acids [2], among 
which Aβ40 and Aβ42 are the most abundant [32]. Aβ40 spe-
cies are soluble and abundantly produced in both healthy 
and AD brains. In contrast, Aβ42 levels are substantially 
increased in AD brains. Because of their high propensity to 
aggregate due to their two additional hydrophobic residues, 
Aβ42 peptides are the main constituents of amyloid depos-
its [36] and many studies have shown that they are highly 
pathogenic in the context of AD [15, 37].
Interestingly, recent studies have pointed to the poten-
tial of other Aβ species, and in particular of Aβ43, to be 
involved in AD pathogenesis. Indeed, Aβ43 is significantly 
Abstract The involvement of Amyloid-β (Aβ) in the 
pathogenesis of Alzheimer’s disease (AD) is well estab-
lished. However, it is becoming clear that the amyloid load 
in AD brains consists of a heterogeneous mixture of Aβ 
peptides, implying that a thorough understanding of their 
respective role and toxicity is crucial for the development 
of efficient treatments. Besides the well-studied Aβ40 and 
Aβ42 species, recent data have raised the possibility that 
Aβ43 peptides might be instrumental in AD pathogenesis, 
because they are frequently observed in both dense and 
diffuse amyloid plaques from human AD brains and are 
highly amyloidogenic in vitro. However, whether Aβ43 is 
toxic in vivo is currently unclear. Using Drosophila trans-
genic models of amyloid pathology, we show that Aβ43 
peptides are mainly insoluble and highly toxic in vivo, 
leading to the progressive loss of photoreceptor neurons, 
altered locomotion and decreased lifespan when expressed 
in the adult fly nervous system. In addition, we demonstrate 
that Aβ43 species are able to trigger the aggregation of the 
typically soluble and non-toxic Aβ40, leading to synergistic 
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increased in AD brains, deposits more frequently than Aβ40 
and is found in the core of amyloid plaques [13, 17, 27, 
30, 36]. Moreover, recent data suggest that Aβ43 is highly 
amyloidogenic in vitro [3, 4, 15, 29] and reduces the viabil-
ity of cultured neuronal cells when applied in the culture 
medium [1, 23, 29]. In addition, higher cortical Aβ43 lev-
els have been associated with increased amyloid load and 
impaired memory in the APP/PS1-R278I transgenic mouse 
model [29].
Importantly, in addition to its ability to self-aggregate in 
vitro to induce neurotoxicity, Aβ43 has been suggested to 
initiate the seeding of other Aβ peptides. Its addition to a 
mixture of Aβ peptides was shown to accelerate the forma-
tion of Thioflavin T-positive amyloid structures in vitro, in 
a more potent manner than did Aβ42 or Aβ40 [29]. In addi-
tion, Aβ43 was shown to deposit earlier than other Aβ spe-
cies in the brain of mouse models of AD [38] and to be sur-
rounded by other Aβ species in brains of AD patients [29], 
further suggesting its ability to nucleate and subsequently 
titrate other Aβ species.
However, a direct in vivo demonstration that Aβ43 self-
aggregates, triggers neurotoxicity and exacerbates neuro-
toxicity from other Aβ species is so far lacking. The fruit 
fly Drosophila has proved an excellent in vivo model sys-
tem for the analysis of both loss of function [10, 25] and 
toxic gain of function [5, 24] human neurodegenerative dis-
eases. We have thus generated inducible transgenic Dros-
ophila lines expressing human Aβ43, Aβ42 or Aβ40, using an 
attP/attB site-directed integration strategy to ensure both 
standard levels of mRNA expression and the best ratio of 
induced versus basal expression [20]. We observed that 
Aβ43 was highly insoluble in vivo and that it led to severe 
toxic effects, both when constitutively expressed in the 
compound eye of the fly, leading to eye roughness, and 
when specifically induced in the adult nervous system, as 
measured by a progressive loss of photoreceptor neurons, 
impaired locomotion and decreased lifespan. Interestingly, 
by combining transgenes encoding different Aβ isoforms 
we also found that, in presence of Aβ43, Aβ40 species were 
progressively shifted from the soluble to the insoluble 
protein fraction and that the overall Aβ insolubility was 
increased, leading to significant defects in climbing ability 
and survival. Altogether, our results demonstrate high path-
ogenicity of Aβ43 species in vivo and delineate their ability 
to trigger toxicity from the otherwise innocuous Aβ40.
Materials and methods
Generation of transgenic fly lines
Human Aβ1–40, Aβ1–42 and Aβ1–43 bearing a secretion signal 
from the Drosophila necrotic gene [6] were synthesized by 
MWG Operon (Germany) using insect optimized codons 
and were subsequently cloned into the pUASTattB vec-
tor. An identical cDNA was used for all sequences that 
were common to all lines. Transgenic fly lines were gen-
erated using the ϕC31 and attP/attB targeted integra-
tion system and transgenes were inserted into the attP40 
or attP2 landing-site loci to ensure both standard levels 
of mRNA expression and the best ratio of induced ver-
sus basal expression [20]. Transgenic fly lines were veri-
fied by sequencing of the corresponding genomic DNA 
and by western blotting (Fig. 1b). The gene-switch Elav-
Gal4 inducible line (elavGS) was derived from the original 
elavGS 301.2 line [26] and obtained as a generous gift from 
Dr. H. Tricoire (CNRS, France). The GMR-Gal4 line was 
obtained from the Bloomington Drosophila Stock Center.
Fly maintenance
All fly stocks were kept at 25 or 29 °C on a 12:12 h 
light:dark cycle at constant humidity and fed with stand-
ard sugar/yeast/agar (SYA) medium (15 g L−1 agar, 
50 g L−1 sugar, 100 g L−1 yeast, 30 mL L−1 nipagin and 
3 mL L−1 propionic acid). All lines were backcrossed into 
a white Dahomey (wDah) wild-type outbred strain for at 
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Fig. 1  Expression of Aβ in fly heads. a qRT-PCR analysis of Aβ 
mRNA levels measured in head extracts of Aβ40, Aβ42 and Aβ43 trans-
genic lines (p > 0.05, one-way ANOVA) following expression in the 
fly nervous system using the neuron-specific elavGS driver. b West-
ern blot analysis of head protein extracts from Aβ40, Aβ42 and Aβ43 
transgenic fly lines (elavGS driver) probed with Aβ40-, Aβ42-, and 
Aβ43-specific antibodies, showing the high specificity of the trans-
genic lines
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least ten generations prior to experiments. Adult-onset 
transgene expression was achieved using the inducible 
gene-switch UAS-Gal4 system and through addition of 
the activator RU486 (Mifepristone) to fly food at a final 
concentration of 200 µM. Non-induced controls were 
obtained by adding the vehicle (i.e. ethanol) to fly food. 
All experimental flies were kept at 25 °C throughout 
development and during the 48-h mating step following 
eclosion, after which females were sorted and transferred 
to 29 °C. Only flies used for the eye phenotype experi-
ment were kept at 25 °C, since an eye phenotype can 
already be observed in the GMR-Gal4 driver control at 
29 °C.
All investigated lines were homozygous for the Aβ 
transgene unless indicated by “1×Aβ”, meaning flies were 
heterozygous for the transgene.
Lifespan analysis
For lifespan experiments, 200 once-mated females per 
group were allocated to vials at a density of 10 flies per vial 
and subsequently kept at 29 °C. Flies were transferred to 
new vials every 2–3 days and the number of dead flies was 
recorded. Lifespan results are expressed as the proportion 
of survivors ±95 % confidence interval.
Climbing assay
Climbing assays were performed blindly using a counter-
current apparatus as previously described [9] using at least 
3 replicates of 20 female flies per group. One hour prior 
to the measurement, flies were randomized and transferred 
to plastic tubes for acclimation. Flies were placed into the 
first chamber of the six-compartment climbing apparatus, 
tapped to the bottom and given 20 s to climb a distance of 
15 cm, after which flies above this level were shifted to 
the second chamber. Both sets of flies were tapped again 
to the bottom and allowed to climb for another 20 s. This 
procedure was repeated for a total of 1 min and 40 s so that 
flies could climb into the six chambers, and the number of 
flies in each chamber was counted at the end of the experi-
ment. The climbing index (CI) was calculated as previ-
ously described [9] and varied between 0 (all flies stayed 
in the first compartment) and 1 (all flies reached the last 
chamber).
Eye phenotype
Eye images of 6-day-old female flies expressing Aβ under 
the control of the GMR-Gal4 driver at 25 °C were taken 
using a Leica M165 FC stereo microscope. At least 8 flies 
per genotype were investigated.
Rhabdomere assay
We used the cornea neutralization technique [8] to visualize 
the rhabdomeres from the ommatidia of the fly compound 
eye. Briefly, dissected fly heads were mounted on a micro-
scope slide using a drop of nail polish and further covered 
with oil. The number of ommatidia lacking rhabdomeres 
was counted using a Leica DMI4000B/DFC 340FX 
inverted microscope and a 40× oil immersion objective. At 
least 50 ommatidia per fly and 5 flies per genotype were 
examined.
Total Aβ levels
20 to 25 female heads per biological replicate were homog-
enized in 100 µL of 70 % formic acid using a disposable 
pellet mixer and a plastic Eppendorf pestle. Samples were 
centrifuged at 16,000g for 20 min at room temperature. 
The supernatant was collected and subsequently evapo-
rated using a SpeedVac. The dry pellet was resuspended in 
100 µL 2× LDS containing reducing agent (Invitrogen) and 
homogenized by sonication (10 pulses). Samples were then 
boiled at 100 °C for 10 min and 10 µL of each sample were 
used for western blotting to determine total Aβ levels.
Fractionation of soluble and insoluble Aβ peptides
The procedure was based on previous reports [7] with 
some modifications. Briefly, 20 female heads per biologi-
cal replicate were homogenized in 100 µL ice-cold RIPA 
buffer (Pierce) supplemented with SDS at a final concen-
tration of 1 % and Complete mini without EDTA protease 
inhibitor (Roche) using a disposable pellet mixer and a 
plastic Eppendorf pestle. Samples were incubated on ice 
for 30 min and were then centrifuged at 100,000g for 1 h 
at 4 °C in an Optima XPN-100 ultracentrifuge (Beckman 
Coulter). The supernatant (“soluble fraction”) was col-
lected and the pellet was homogenized in 100 µL of 70 % 
formic acid by pipetting, followed by 5-min incubation 
in a sonication bath. Samples were centrifuged again at 
100,000g for 1 h at 4 °C, after which the supernatant was 
collected (“insoluble fraction”) and evaporated using a 
SpeedVac. The dry pellet was then resuspended in 100 µL 
2× LDS containing reducing agent (Invitrogen) by pipet-
ting followed by 5-min incubation in a sonication bath. 
Protein concentration of the soluble fraction was measured 
using the BCA protein assay kit (Pierce), and 30 µg of solu-
ble proteins and equivalent volumes of insoluble proteins 
were used for western blotting. Results are represented as 
the proportion of insoluble Aβ species, i.e. insoluble Aβ/
(soluble Aβ + insoluble Aβ) × 100. Results are expressed 
as mean ± sem.
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Sample preparation for soluble Aβ oligomers and dot 
blotting
The procedure was based on previous reports [21] with 
some modifications. Briefly, 20 female heads per biologi-
cal replicate were homogenized in 100 µL ice-cold 1× 
PBS buffer supplemented with Complete mini without 
EDTA protease inhibitor (Roche) using a disposable pellet 
mixer and a plastic Eppendorf pestle. Samples were then 
ultra-centrifuged at 78,000g for 1 h at 4 °C. The superna-
tant, i.e. the PBS-soluble fraction was collected and protein 
concentration was measured using the BCA protein assay 
kit (Pierce). One microlitre per sample (corresponding to 
1.5 µg of proteins) was spotted onto a 0.2 µm nitrocellu-
lose membrane (GE Healthcare) and let to dry for 30 min. 
The membrane was then blocked in TBS-low tween buffer 
(containing 0.01 % Tween) with 10 % non-fat dry milk 
for 1 h at room temperature, incubated overnight at 4 °C 
with the A11 anti-oligomer antibody (1/1000, Invitrogen) 
and then for 1 h at room temperature with HRP-conjugated 
anti-rabbit antibody (1/10,000, Invitrogen). Detection was 
performed using ECL prime chemiluminescence kits (GE 
Healthcare) and Hyperfilms (GE Healthcare).
Sample preparation for LDS/SDS‑stable Aβ oligomers
20 female heads per biological replicate were homogenized 
in 100 µL 2× LDS containing reducing agent (Invitrogen) 
using a disposable pellet mixer and a plastic Eppendorf 
pestle. Sample were incubated on ice for 30 min and were 
then boiled at 100 °C for 10 min. 15 µL per sample were 
used for western blotting to evaluate LDS/SDS-stable Aβ 
oligomers.
Western blotting
Protein samples were separated on 16.5 % Tris-Tricine Cri-
terion gels (Biorad) and subsequently transferred to 0.2 µm 
nitrocellulose membranes (GE Healthcare). After a boil-
ing step of 4 min in 1× PBS, membranes were blocked in 
TNT buffer (Tris–HCl 15 mM pH 8, NaCl 140 mM, 0.05 % 
Tween) with 5 % non-fat dry milk for 1 h at room tem-
perature and incubated overnight at 4 °C with the follow-
ing primary antibodies: anti-Aβ1–16 mAb (6E10, 1/5000, 
Covance), anti-Aβ1–40 mAb (9682, 1/500, Cell Signaling), 
anti-Aβ1–42 mAb (12F4, 1/500, Covance), anti-Aβ1–43 mAb 
(9C4, 1/500, Covance), anti-α-tubulin (11H10, 1/5000, 
Cell Signaling) and anti-β-actin (1/100,000, Abcam). 
HRP-conjugated anti-mouse or anti-rabbit antibodies 
(1/10,000, Invitrogen) were used for 1 h at room tempera-
ture and detection was performed using ECL or ECL prime 
chemiluminescence kits (GE Healthcare) and Hyperfilms 
(GE Healthcare). Bands were quantified using the ImageJ 
software (Scion Software) and results are expressed as 
mean ± sem.
Immunofluorescence
After decapitation and removal of proboscis, heads of 
20-day-old GMR-Gal4-driven Aβ flies were fixed for 
3 h in 4 % paraformaldehyde in PBS and then incubated 
overnight in 25 % sucrose in PBS. Heads were fro-
zen in Tissue-Tek O.C.T. (Sakura Finetek) and kept at 
−80 °C until use. Immunofluorescence was performed on 
16 µm cryosections using an anti-Aβ1–40 mAb antibody 
(D8Q71, 1/200, Cell Signaling) followed by anti-rabbit 
Alexa-488 secondary antibody (1/250, Invitrogen), both 
being diluted in PBS with 0.1 % Triton and 5 % non-fat 
dry milk. An incubation step of 3 min in 70 % formic 
acid was included prior to blocking to unmask antigens. 
Stained sections were mounted using Vectashield with 
DAPI (Vector) and analysed with a Leica DMI4000B/
DFC 340FX inverted microscope. Quantification of Aβ40 
deposits was performed using ImageJ from at least 6 flies 
per genotype.
RNA extraction and qRT‑PCR
Total RNA was extracted from 25 female heads per rep-
licate using a Trizol-Chloroform-based procedure (Invit-
rogen) and subsequently treated with DNAse I (Ambion). 
300 ng of RNA were then subjected to cDNA synthesis 
using the SuperScript Vilo Mastermix (Invitrogen). Quan-
titative real-time PCR was performed using TaqMan 
primers (Applied Biosystems) in a 7900HT real-time 
PCR system (Applied Biosystems). RPL32 and actin5c 
were used as normalization controls and the relative 
expression of target genes was determined by the ΔΔCT 
method. Six independent biological replicates per group 
were analysed. Results are expressed as a percentage of 
the corresponding control transgenic line and are plotted 
as mean ± sem.
Statistical analysis
For lifespan experiments, statistical differences were 
assessed using the log-rank test. Eye phenotypes were 
statistically evaluated using the Fisher’s exact test. Other 
results are expressed as mean ± sem and differences 
between mean values were determined using either Stu-
dent’s t test, one-way ANOVA followed by Tukey’s post 
hoc test or two-way ANOVA followed by Tukey’s post hoc 
test, using Graphpad Prism software. p values <0.05 were 
considered significant.
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Results
We generated transgenic Drosophila lines expressing 
human Aβ43, Aβ42 or Aβ40, using a site-directed integra-
tion strategy to allow transgene insertion into the same 
genomic locus and therefore ensure equivalent levels of 
Aβ mRNA expression among the lines, as verified by qRT-
PCR (p > 0.05, Fig. 1a). Specific expression of individual 
Aβ species was checked by western blot using C-terminal-
specific, anti-Aβ antibodies (Fig. 1b), confirming that each 
transgenic line was expressing a single Aβ species.
We first examined the effect of human Aβ homozygous 
over-expression in Drosophila eyes, using the constitutive, 
eye-specific GMR-Gal4 driver. While the eyes of Aβ40-
expressing flies were not affected and appeared similar 
to those of the driver line control, Aβ43 expression led to 
ommatidial disorganization and eye roughening, indicat-
ing that Aβ43 was able to induce toxicity in vivo (Fig. 2a). 
Quantification of the observed rough eye phenotypes 
among the lines confirmed a significant toxic effect of Aβ43 
expression (**p < 0.01, Aβ43 vs. Aβ40 and Aβ43 vs. GMR 
driver control, Fisher’s exact test, supplementary Fig. 1), 
although this effect was significantly milder than the one 
induced by Aβ42 (#p < 0.05 and *p < 0.05, Aβ43 vs. Aβ42, 
Fisher’s exact test, supplementary Fig. 1). We then used 
the pan-neuronal and RU486-inducible elav-GeneSwitch-
Gal4 (elavGS) driver [28] to investigate the effects on fly 
climbing ability and survival of the expression of human 
Aβ specifically in adult neurons. As expected from pre-
vious reports [7, 33], adult-restricted, neuronal expres-
sion of Aβ42 led to severe toxic effects, both on climbing 
ability (p < 0.0001 vs. non-induced controls after 11 and 
18 days of induction, two-way ANOVA, Fig. 2b) and on 
fly survival (median lifespan: −52.4 % of non-induced 
controls, p < 0.0001, log-rank test, Fig. 2c), while induc-
tion of Aβ40 produced no overt defects in climbing ability 
(p > 0.05 vs. non-induced controls at all investigated ages, 
two-way ANOVA, Fig. 2b) or survival (median lifespan: 
−5.6 % of non-induced controls, Fig. 2c), similar to what 
we observed for the driver line control (climbing ability: 
p > 0.05 at all investigated ages using two-way ANOVA, 
supplementary Fig. 2a; median lifespan: −6.3 % of non-
RU486-fed controls, supplementary Fig. 2b). In line with 
the toxicity measured following its specific over-expression 
in the fly eye, inducing Aβ43 expression in the adult nerv-
ous system severely impaired fly climbing performance 
(****p < 0.0001 vs. non-induced controls after 18 days 
of induction, two-way ANOVA, Fig. 2b), although the 
induced toxicity was significantly milder than follow-
ing Aβ42 expression (p < 0.0001 and p < 0.001 after 11 
and 18 days of induction, respectively, induced-Aβ42 vs. 
induced-Aβ43, two-way ANOVA, Fig. 2b). Survival showed 
a similar pattern, with neuronal expression of Aβ43 leading 
to a severe shortening of median lifespan, corresponding to 
−41.6 % of the non-induced controls (p < 0.0001, log-rank 
test, Fig. 2c). Our results therefore demonstrate strong tox-
icity from Aβ43 over-expression in adult neurons.
To investigate whether neuronal expression of Aβ 
resulted in neuronal degeneration, we used the quantita-
tive pseudopupil technique to analyse the loss of photo-
receptor neurons from the fly compound eye [8, 14, 35]. 
Each ommatidium from the fly eye contains seven visible 
photoreceptor neurons that produce photosensitive struc-
tures called rhabdomeres. We evaluated the proportion 
of ommatidia showing a loss of rhabdomeres following 
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Fig. 2  Aβ43 expression led to detrimental effects on fly eye appear-
ance, climbing ability and survival. a Representative microphoto-
graphs of adult fly eyes upon Aβ over-expression using the consti-
tutive, eye-specific GMR-Gal4 driver. Control eyes were obtained 
from the GMR-Gal4 driver line, which do not over-express any Aβ 
peptide. Climbing ability (b) and survival curves (c) of RU486-
induced (plain curves) and non-induced (dotted curves) Aβ40 (blue), 
Aβ42 (purple) and Aβ43 (red) transgenic flies. The inset shows the 
percentage of median lifespan reduction versus non-induced control. 
****p < 0.0001 versus non-induced controls, two-way ANOVA
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Aβ expression in adult neurons (Fig. 3, the bottom inset 
showing an ommatidium lacking the central rhabdomere, 
to be compared with a normal ommatidium in Fig. 3, 
top inset). While expression of Aβ40 led to no significant 
loss of photoreceptor neurons as compared to the elavGS 
driver control (p > 0.05 vs. age-matched controls, at all 
investigated ages, Fig. 3), Aβ42-expressing flies displayed 
a progressive and pronounced neurodegeneration, the per-
centage of affected ommatidia reaching 10.48 ± 1.93 % 
at day 13 (***p < 0.001 vs. age-matched elavGS control, 
one-way ANOVA, Fig. 3) and 20.02 ± 2.52 % at day 19 
(***p < 0.001 vs. age-matched elavGS control, one-way 
ANOVA, Fig. 3). Interestingly, we found that the expres-
sion of Aβ43 in adult neurons also triggered progressive 
loss of rhabdomeres with age (p < 0.01, one-way ANOVA), 
affecting 3.18 ± 0.79 and 8.64 ± 2.28 % of ommatidia at 
day 19 and 25, respectively, the latter being significantly 
higher than the effect observed in both elavGS controls 
and Aβ40-expressing flies (*p < 0.05 vs. 25-day-old elavGS 
driver controls and p < 0.01 vs. 25-day-old Aβ40 transgenic 
line, one-way ANOVA, Fig. 3), showing that Aβ43 pep-
tides led to neurodegeneration in vivo. This neuronal loss 
was significantly milder than that observed following Aβ42 
over-expression (p < 0.001 at day 13 and day 19, Aβ43 vs. 
Aβ42, one-way ANOVA; note that all Aβ42-expressing flies 
were dead at day 25). Altogether, our data demonstrate 
the ability of Aβ43 peptides to trigger toxicity and neuro-
degeneration in Drosophila, and suggest that the toxic 
effects are significantly milder than those induced by Aβ42 
over-expression.
Since Aβ mRNA levels were comparable among the 
lines as measured by quantitative real-time PCR (Fig. 1a), 
we hypothesized that the different degrees of toxicity 
induced by over-expression of Aβ40, Aβ42 or Aβ43 could 
be explained by a differential stability of the Aβs at the 
peptide level. We therefore measured the total levels of 
Aβ peptides retrieved from fly heads following Aβ induc-
tion in the adult nervous system, using an antibody bind-
ing to the N-terminal region of Aβ that is common to all 
three peptides. First, we analysed total Aβ levels at a very 
early time point, following 4 h of RU486 induction, and 
we observed no significant difference between the lines 
(p > 0.05, one-way ANOVA, Fig. 4a). However, as early as 
1 day following the beginning of transgene induction, we 
could already observe that total Aβ amounts significantly 
differed between the lines, with levels of Aβ40 and Aβ43 
representing 55.92 ± 3.45 and 79.30 ± 2.55 % of Aβ42 
levels, respectively (*p < 0.05 and ***p < 0.001, one-way 
ANOVA, Fig. 4b). Such differences intensified with time. 
Total Aβ peptide levels measured in the Aβ40-expressing 
line were extremely low compared to Aβ42 transgenics after 
5 days of induction (2.79 ± 1.32 % relative to Aβ42 lev-
els, ***p < 0.001, one-way ANOVA, Fig. 4c), in line with 
previous reports [7]. We also observed that total levels of 
Aβ were markedly lower in the Aβ43 than in the Aβ42 trans-
genics after 5 days of induction (33.60 ± 7.96 % relative 
to Aβ42 levels, ***p < 0.001, one-way ANOVA, Fig. 4c), 
but significantly higher than those retrieved from the heads 
of Aβ40 transgenic flies (*p < 0.05, one-way ANOVA, 
Fig. 4c).
These results suggest that these Aβ isoforms differen-
tially accumulate in the fly nervous system. Such effects 
could be explained by a differential aggregation propensity 
and therefore protein stability of these three Aβ species. To 
tackle this question, we performed fractionation experi-
ments to evaluate whether Aβ40, Aβ42 and Aβ43 would dis-
play an unequal propensity to form amyloid structures in 
vivo in the adult fly brain, as previously suggested by in 
vitro studies [4, 29]. Interestingly, fractionation of Aβ pep-
tides according to their solubility in 1 % SDS revealed dif-
ferences among the lines as early as 1 day following the 
start of induction in the fly nervous system. We confirmed 
previous reports from Drosophila [7, 12] of a high solu-
bility of Aβ40 species (0.48 ± 0.10 and 1.61 ± 0.66 % of 
Aβ40 species being insoluble after 1 and 5 days of induc-
tion, respectively, Fig. 4d) while most of the Aβ42 was 
found in the insoluble fraction (51.92 ± 2.94 % at day 1 
and 94.76 ± 1.61 % at day 5, ****p < 0.0001 vs. Aβ40, 
one-way ANOVA, Fig. 4d), suggesting that Aβ42 peptides 
form insoluble structures when expressed in adult fly neu-
rons. Interestingly, 1 day after the beginning of induction, 
a significantly higher proportion of Aβ43 peptides than 
Aβ40 were found in an insoluble state (30.30 ± 1.50 %, 
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Fig. 3  Aβ43 expression led to progressive neurodegeneration. The 
percentage of ommatidia lacking rhabdomeres was quantified from 
the RU486-induced Aβ40, Aβ42 and Aβ43 transgenic fly lines and 
elavGS driver control at three different time points [13 (white), 19 
(grey) and 25 (black) days of induction, *p < 0.05 and ***p < 0.001 
vs. age-matched elavGS driver control]. Insets show representative 
micrographs of the rhabdomeres from a normal ommatidium (a) and 
from an ommatidium lacking the central rhabdomere (b). All Aβ42-
expressing flies were dead at day 25
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****p < 0.0001 vs. Aβ40, one-way ANOVA, Fig. 4d), 
although they were more soluble than Aβ42 peptides 
(***p < 0.001 vs. Aβ42, one-way ANOVA, Fig. 4d). The 
proportion of insoluble Aβ43 rose to 89.17 ± 0.99 % 
after 5 days of induction (****p < 0.0001 vs. Aβ40, one-
way ANOVA, Fig. 4d), indicating that Aβ43 peptides were 
mostly insoluble at this stage. However, Aβ43 was still sig-
nificantly more soluble than Aβ42 (*p < 0.05, Aβ43 vs. Aβ42, 
one-way ANOVA, Fig. 4d).
Such drastic differences in Aβ solubility might reflect 
differential ability of cells to clear Aβ peptides. To test this 
hypothesis, we performed a “switch-on/switch-off” experi-
ment, in which flies were first exposed to the RU486 inducer 
for a period of 5 days (“5d ON”), to activate neuronal Aβ 
expression, and then transferred to RU486-free food for 
either 2 or 7 days (“5d ON + 2d OFF” and “5d ON + 7d 
OFF”, respectively) to evaluate Aβ clearance either shortly 
following induction arrest or at a later stage to ensure the 
complete removal of RU486 from the fly nervous system 
[26, 28]. A parallel cohort was exposed to the inducer for 
the entire duration of the experiment, i.e. 12 days (“12d 
ON”). Using the 6E10 pan-Aβ antibody, we evaluated the 
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total levels of Aβ retrieved from fly head extracts under 
these conditions (Fig. 5). Interestingly, clearance of Aβ 
appeared strikingly different depending on the investi-
gated isoform. While Aβ40 was rapidly cleared from the fly 
nervous system, with 19.26 ± 3.03 and 0.36 ± 0.04 % of 
Aβ40 remaining 2 and 7 days following induction arrest, 
respectively (relative to the levels measured directly fol-
lowing 5 days of induction; ****p < 0.0001, 5d ON + 2d 
OFF vs. 5d ON and **p < 0.01, 5d ON + 7d OFF vs. 5d 
ON + 2d OFF, one-way ANOVA, Fig. 5a, b), we could 
not observe any reduction in Aβ42 levels 2 days following 
induction arrest (Fig. 5a). Rather, Aβ42 appeared to accumu-
late in the fly nervous system, reaching 349.25 ± 50.77 % 
of the levels observed before the switch to RU486-free con-
ditions (**p < 0.01, 5d ON + 2d OFF vs. 5d ON, one-way 
ANOVA, Fig. 5b). Seven days following induction arrest, 
Aβ42 levels represented 209.91 ± 33.60 % of the initial 
“5d ON” levels, suggesting that the clearance process of 
accumulated Aβ42 was effective at this stage (*p < 0.05, 5d 
ON + 7d OFF vs. 5d ON + 2d OFF, one-way ANOVA, 
Fig. 5a, b), although the retrieved Aβ42 amounts did not 
reach lower levels than those measured in the “5d ON” 
condition (p > 0.05, 5d ON + 7d OFF vs. 5d ON, one-
way ANOVA, Fig. 5b). Interestingly, the behaviour of 
Aβ43 following induction arrest appeared strikingly differ-
ent from that of both Aβ40 and Aβ42. Whereas 2 days fol-
lowing induction arrest there was a trend for reduced Aβ43 
amounts (40.18 ± 9.90 % vs. 5d ON, p > 0.05 using one-
way ANOVA, Fig. 5a, b), we could not observe any further 
change in Aβ43 levels following 7 days of induction arrest 
(p > 0.05, 5d ON + 7d OFF vs. 5d ON + 2d OFF, one-
way ANOVA, Fig. 5a, b). Additionally, the analysis of Aβ43 
amounts retrieved from head extracts following 12 days 
of RU486-induced expression revealed a significant 
Aβ43 accumulation in the fly nervous system upon induc-
tion (248.09 ± 20.84 % at 12d ON relative to 5d ON lev-
els, **p < 0.01, one-way ANOVA, Fig. 5a, b), while Aβ40 
expression appeared to yield rather stable total Aβ levels 
over time (127.27 ± 19.09 % at 12d ON, p > 0.05 vs. 5d 
ON, one-way ANOVA, Fig. 5a, b). In contrast, Aβ42 accu-
mulation was striking, reaching after 12 days of induction 
525.70 ± 46.10 % of the levels observed following 5 days 
of induction (***p < 0.001, one-way ANOVA, Fig. 5a, b). 
Altogether, these results suggest on one hand that Aβ43 
peptides accumulate in the fly nervous system, though to 
a lower extent than Aβ42, and on the other hand that cells 
appear to be less efficient in the clearance of Aβ43 as com-
pared to that of Aβ40. Together with the phenotypic effects 
of these Aβ isoforms (Figs. 2, 3), these results suggest that 
Aβ43-induced toxicity is related to its high propensity to 
self-aggregate and accumulate in vivo.
As increasing evidence suggest that toxic Aβ oligomers 
are important effectors of neurodegeneration (for review, 
see [2]), we evaluated the presence of PBS-soluble Aβ 
oligomeric species in our transgenic Aβ fly lines by dot 
blotting (supplementary Fig. 3a). Immuno-labelling of 
the membrane with the A11 anti-oligomer antibody did 
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extracts following neuronal (elavGS-driven) expression of Aβ40 (top 
panel), Aβ42 (middle panel) or Aβ43 (lower panel) following either 
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not highlight any specific signal corresponding to soluble 
oligomers in our transgenic Aβ lines as compared to the 
elavGS driver control (p > 0.05, one-way ANOVA, sup-
plementary Fig. 3a). However, since this antibody is not 
expected to detect low-molecular weight (MW) Aβ oli-
gomers [16, 18], we performed western blotting on head 
extracts using the 6E10 pan-Aβ antibody to examine LDS/
SDS-stable Aβ assemblies (supplementary Fig. 3b, c). The 
major LDS/SDS-stable Aβ species for all transgenic lines 
was monomeric (1-mer, short exposure time, supplemen-
tary Fig. 3b), however, longer exposure time revealed the 
presence of specific 6E10-positive bands of higher MWs, 
corresponding to the apparent size of Aβ dimers (2-mer, 
8 kDa), trimers (3-mer, 12 kDa) and tetramers (4-mer, 
16 kDa). Interestingly, the oligomeric profile was different 
for the investigated Aβ species, with a relative abundance 
of dimers for the Aβ42 line and of trimers for the Aβ43 line, 
while no LDS/SDS-stable low-MW Aβ oligomers could be 
observed in Aβ40-expressing flies (supplementary Fig. 3b, 
c).
Noteworthy, next to its propensity to self-aggregate, 
Aβ43 has also been implicated in the seeding of other Aβ 
peptides based on in vitro data and co-localisation stud-
ies [29, 38], an effect potentially enhancing overall Aβ 
toxicity. To test whether this process occurred in vivo, we 
used our Drosophila transgenic lines to stoichiometrically 
induce Aβ43 expression together with that of the non-toxic 
Aβ40 and to evaluate whether this combination would trig-
ger toxicity. To that end, we titrated down Aβ43 levels by 
halving transgene copy number from two copies to one, 
leading to no detectable toxicity in terms of climbing abil-
ity (1×Aβ43, Fig. 6a) or median lifespan (1×Aβ43, Fig. 6b), 
similar to the effects obtained following halved expression 
of Aβ40 (1×Aβ40, Fig. 6a, b). While combining Aβ40 with 
Aβ40 itself (Aβ40+Aβ40) did not lead to any phenotypic 
changes as compared to Aβ40 alone (p > 0.05, Fig. 6a, b), 
we observed that the combination of low levels of both Aβ40 
and Aβ43 induced synergistic toxic effects both on climb-
ing ability (****p < 0.0001 vs. non-induced-Aβ40+Aβ43 
controls and vs. all other induced lines at day 25, two-way 
ANOVA, Fig. 6a) and survival (median lifespan: −15.7 % 
of the non-induced controls, p < 0.0001, log-rank test, 
Fig. 6b), suggesting that Aβ43 was able to trigger toxicity 
from Aβ40 peptides in vivo, despite the ordinarily harmless 
nature of the latter. We used the same experimental setup to 
co-express Aβ40 with Aβ42 (supplementary Fig. 4), which 
led to drastic detrimental effects, both on climbing abil-
ity (****p < 0.0001 vs. non-induced-Aβ40+Aβ42 controls 
and vs. all other induced lines at day 18, two-way ANOVA, 
supplementary Fig. 4a) and survival (median lifespan: 
−46.7 % of the non-induced controls, p < 0.0001, log-rank 
test, supplementary Fig. 4b). Even though both Aβ40+Aβ42 
and Aβ40+Aβ43 combinations led to significant synergistic 
toxic effects in the fly nervous system, it appeared that the 
former triggered stronger toxicity. We therefore investi-
gated whether Aβ43 could modulate Aβ42 toxicity by com-
paring the effect of Aβ42+Aβ43 with that of Aβ42+Aβ42 
on climbing ability and survival of flies (supplementary 
Fig. 5). We could observe a rather modest but yet signifi-
cant reduction of toxicity in the combined Aβ42+Aβ43 line 
both in terms of climbing (**p < 0.01, induced-Aβ42+Aβ43 
vs. induced-Aβ42+Aβ42, two-way ANOVA, supplementary 
Fig. 5a) and survival (p < 0.0001, induced-Aβ42+Aβ43 vs. 
induced-Aβ42+Aβ42, log-rank test, supplementary Fig. 5b). 
Importantly, we evaluated Aβ transcript levels among the 
lines in all three experiments and observed that they were 
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comparable (p > 0.05, Aβ40+Aβ40 vs. Aβ40+Aβ43, Fig. 6c, 
Aβ40+Aβ40 vs. Aβ40+Aβ42, supplementary Fig. 4c, and 
Aβ42+Aβ42 vs. Aβ42+Aβ43, supplementary Fig. 5c, using 
Student’s t test), implying that the toxic interaction we 
observed between the Aβ isoforms was taking place at the 
protein level.
To verify this assumption and to further assess the 
potential seeding properties of Aβ43, we performed 
fractionation of Aβ according to its solubility in both 
Aβ40+Aβ43 and Aβ40+Aβ40 combined lines. Using the 
6E10 pan-Aβ antibody (Fig. 7a), we observed a dramatic 
decrease of Aβ solubility in the combined Aβ40+Aβ43 con-
dition as compared to the Aβ40+Aβ40 line, with insoluble 
Aβ species representing 57.89 ± 0.79 % of the total Aβ 
pool in the former line (****p < 0.0001, vs. Aβ40+Aβ40, 
Student’s t test, Fig. 7a, b). To determine whether this 
insoluble Aβ pool was holding Aβ40 species, which are 
intrinsically mainly soluble, we analysed the soluble and 
insoluble protein fractions using an antibody specifically 
targeting Aβ40 species (Fig. 8a). This revealed a progres-
sive shift of Aβ40 species towards the insoluble fraction in 
the Aβ40+Aβ43 line as compared to the Aβ40+Aβ40 condi-
tion, the former having 33.37 ± 1.04 % of its Aβ40 spe-
cies located in the SDS-insoluble fraction after 5 days 
of induction (vs. 8.64 ± 0.50 % for the Aβ40+Aβ40 line, 
***p < 0.001, Student’s t test, Fig. 8b), while this pro-
portion reached 87.11 ± 2.09 % after 14 days of induc-
tion (vs. 30.55 ± 2.49 % for the Aβ40+Aβ40 line, 
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Fig. 9  Combining Aβ40 with Aβ43 enhanced Aβ40 immunoreactivity 
in fly compound eyes. Cryosections from heads of Aβ40+Aβ40- and 
Aβ40+Aβ43-expressing fly lines and of the GMR-Gal4 driver control 
line were probed with an Aβ40-specific antibody (green) and counter-
stained with DAPI (blue) and the number of Aβ40-positive events per 
eye section was quantified (****p < 0.0001, Student’s t test). Scale 
bar 50 µm
45Acta Neuropathol (2015) 130:35–47 
1 3
****p < 0.0001, Student’s t test, Fig. 8c), implying that 
Aβ43 was a potent trigger of Aβ40 aggregation in vivo. To 
strengthen this observation, we performed immunofluores-
cence experiments on cryosections from Drosophila heads 
following Aβ over-expression in the compound eye, using 
an antibody specific to Aβ40. While the signal appeared 
predominantly diffuse in the Aβ40+Aβ40 expressing line, 
we observed a marked accumulation of Aβ40 species in the 
eye of the Aβ40+Aβ43 transgenic line (****p < 0.0001, 
Aβ40+Aβ40 vs. Aβ40+Aβ43, Student’s t test, Fig. 9), 
which is in line with the biochemical shift of Aβ40 species 
towards the insoluble protein fraction that we observed in 
the latter combination (Fig. 8). Altogether, our data indi-
cate that Aβ43 species influence Aβ40 properties leading to 
its decreased solubility, which subsequently results in a 
significant enhancement of toxicity in vivo.  
Discussion
While the amyloid load is built up by a mixture of Aβ pep-
tides in AD brains [2], the respective involvement of these 
species in AD pathogenesis remains unsolved. Using induc-
ible transgenic Drosophila lines expressing human Aβ, we 
demonstrated in the present study that Aβ43 peptides not 
only self-aggregate and lead to toxicity and neurodegen-
eration in vivo but also that they can trigger neurotoxicity 
from the otherwise innocuous Aβ40 peptides.
Our transgenic fly lines are based on the direct pro-
duction of secretory Aβ species. Even though this model 
bypasses the secretase-based generation of Aβ from its APP 
precursor, potentially altering the normal trafficking route 
and sub-cellular localisation of APP and consequently of 
Aβ, the choice of directly expressing secretory forms of the 
different Aβ isoforms was crucial to ensure controlled and 
comparable levels of Aβ peptides produced upon induced 
expression in the fly nervous system. In addition, by gen-
erating transgenic lines using the attP/attB targeted integra-
tion system [20], we ensured that insertion of the different 
Aβ transgenes would take place into the same genomic 
locus, thereby reducing the risk of a differential promoter 
regulation due to a different genomic environment. In this 
way, we ensured that any observed toxic effect would not 
be a consequence of different transcript levels, which could 
have otherwise confounded the results, but would instead 
directly result from differential regulation occurring at the 
protein level. As an additional control to confirm the com-
parability of our transgenic lines, we measured the levels 
of Aβ peptide produced after a very short induction time, 
i.e. 4 h. We observed no significant difference in Aβ pep-
tide levels between the Aβ transgenic fly lines at this stage, 
suggesting that translation from Aβ transcripts and there-
fore Aβ peptide synthesis was occurring at a similar rate, 
ruling out any potential differences in terms of translation 
efficiency among the analysed transgenic lines.
Interestingly, however, we observed that the amounts of 
total Aβ40, Aβ42 or Aβ43 retrieved from Drosophila heads 
became increasingly different with longer induction times. 
Since transcription and baseline Aβ peptide levels were 
comparable for all the lines, we hypothesized that such 
regulation at the peptide level was rather a consequence of 
altered clearance dynamics. Indeed, by means of a “switch-
on/switch-off” experiment, where the RU486 inducer was 
removed after a period of 5 days, we could observe strik-
ing differences regarding the clearance of these Aβ iso-
forms. Such differential effects are likely to be linked to 
the unequal propensity of these Aβ species to form SDS-
insoluble assemblies, as suggested by the differential kinet-
ics of aggregation displayed by the Aβs. Indeed, among all 
three isoforms, we could observe that Aβ42 was the fastest 
isoform to generate SDS-insoluble species. Furthermore, 
even though the kinetics of Aβ43 aggregation in the fly 
nervous system was significantly slower than that of Aβ42 
as observed after 1 day of induction, it was markedly faster 
than that of Aβ40, which mainly remained in a SDS-solu-
ble state throughout the experiment. As compared to Aβ40, 
Aβ42 peptides hold two additional hydrophobic residues 
that greatly increase their propensity to aggregate [3, 15]. 
Moreover, recent in vitro studies [3, 15, 29] suggest that 
Aβ43, which bears an additional threonine in its C-terminal 
compared to Aβ42, displays even greater amyloidogenic 
properties than the latter. Our findings, however, suggest 
that when directly expressed in the fly nervous system, Aβ43 
species shift towards an insoluble state with a slower kinet-
ics than Aβ42. Although this would require further investi-
gation, one might speculate that the molecular environment 
found in neuronal cells in vivo influences the kinetics of Aβ 
aggregation as compared to the behaviour of these peptides 
in vitro. It is important to note that, even when Aβ43 was 
found in a highly insoluble state in the fly nervous system, 
i.e. following 5 days of expression, the overall proportion 
of SDS-insoluble Aβ43 species was significantly lower 
than that of Aβ42, suggesting that the additional threonine 
in Aβ43 provides the peptide with an overall higher polar-
ity and therefore lower amyloidogenicity than Aβ42. Alto-
gether, our results suggest that Aβ40, Aβ42 and Aβ43 display 
a differential stability in vivo even when expressed at com-
parable levels, an effect that is likely related to their une-
qual propensity to form SDS-insoluble species, eventually 
influencing the ability of the cells to clear them.
Recent cell culture studies suggested that Aβ43 peptides 
are highly cytotoxic, significantly more so than Aβ40 pep-
tides [1, 29]. In line with these data, we measured strong 
toxic effects resulting from Aβ43 expression in either Dros-
ophila compound eyes or Drosophila adult neurons, as 
compared to the effects of Aβ40. However, we observed 
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that in vivo, Aβ43 peptides were significantly less harmful 
than Aβ42 for all measured phenotypes, i.e. eye appearance, 
climbing ability, survival and neurodegeneration. Among 
the few cell culture studies that have so far investigated 
Aβ43, the relative cytotoxicity of the latter as compared to 
Aβ42 is still a matter of debate, some studies highlighting 
a higher toxicity of Aβ43 [23, 29], others suggesting that 
Aβ42 is more toxic [1]. Our in vivo results support the latter 
hypothesis, and it appears that in our system the observed 
differential toxic effects correlate with the unequal pro-
pensity of the Aβs to aggregate and therefore to be cleared 
from the cells, in agreement with several studies in Dros-
ophila showing that Aβ toxicity is correlated with its pro-
pensity to form insoluble aggregates [11, 19, 34].
Nevertheless, given the increasing amount of data sug-
gesting that soluble Aβ oligomers are important drivers of 
neurotoxicity in AD and AD models (for review, see [2]), 
together with recent data suggesting that Aβ43 assembles 
into soluble oligomers in vitro [31], we further analysed 
the potential occurrence of Aβ oligomers in our transgenic 
lines using the A11 oligomer-specific antibody. However, 
we could not highlight any PBS-soluble A11-positive oli-
gomers in our lines, in agreement with previous studies 
analysing Aβ42 transgenic Drosophila [11]. However, since 
the A11 antibody does not detect low-MW Aβ oligomers, 
we used the pan-Aβ 6E10 antibody on western blot [18, 
22] and could observe the presence of LDS/SDS-stable 
Aβ assemblies at the apparent MW of dimers, trimers and 
tetramers, the relative abundance of which differed among 
the investigated Aβ lines. While our results highlight the 
relative abundance of LDS/SDS-stable Aβ43 trimers and 
confirm published data that Aβ42 can form dimers in Dros-
ophila [6, 11], further investigation will be required to deci-
pher the potential contribution of these LDS/SDS-stable Aβ 
assemblies to the observed phenotypes.
Another important question in the context of AD, where 
several different Aβ species are found in brain deposits, 
is whether Aβ43 peptides could exacerbate neurotoxicity 
from other Aβ species in vivo. Therefore, we investigated 
whether Aβ43 could trigger toxicity from the non-toxic Aβ40 
peptides in Drosophila. To that end, we reduced Aβ expres-
sion levels to a point where no toxicity could be detected, 
either on climbing ability or survival, by halving the Aβ 
transgene copy number from two to one. We combined 
one copy of each, Aβ40 with Aβ43 and as a control, Aβ40 
with Aβ40 itself and, importantly, the measured overall Aβ 
transcript levels were comparable between these combina-
tions. The Aβ40+Aβ43 combination was significantly more 
toxic on one hand than Aβ43 alone, despite identical Aβ43 
transgene copy number, and on the other hand than the 
Aβ40+Aβ40 combination, even though the overall Aβ tran-
script levels did not differ between the conditions. At the 
protein level, the combination of Aβ40 with Aβ43 increased 
the proportion of SDS-insoluble Aβ40 species as compared 
to the Aβ40+Aβ40 line, and shifted the overall Aβ con-
tent towards a more insoluble state, suggesting that toxic-
ity arose from an increased propensity to form insoluble 
structures in the Aβ40+Aβ43 combined line. Together with 
published observations that Aβ43 peptides can be found in 
plaque cores in AD brains [29, 36] and that they deposit 
earlier than other Aβ species in the brain of mouse models 
of AD [38], our data suggest that Aβ43 is involved in the 
titration of Aβ40 and potentially of other Aβ peptides into 
insoluble structures, therefore acting as a nucleating factor 
in AD brains. Our results, however, suggest that Aβ43 does 
not further exacerbate toxicity of the already extremely 
harmful Aβ42 in Drosophila.
In summary, our findings indicate a remarkable pathogenic-
ity of Aβ43 peptides, not only because they self-aggregate 
and exert potent neurotoxic effects in vivo, but also because 
of their ability to trigger aggregation and toxicity from other 
Aβ species. Our results delineate the important contribution of 
Aβ43 peptides to the pathological events leading to neurode-
generation in AD, and suggest that these species represent a 
relevant target for the treatment of this disease.
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